ISSN 0303-5212
 

Original Research 
RMJ. 2020; 45(3): 611-615


Oral versus topical propranolol in infantile hemangiomas

Abdul Hameed Khan, Gulwish Salah u Din, Jawaria Irshad, Anam Altaf.

Abstract
Objective: To determine the therapeutic response rate of oral and topical propranolol in infantile hemangiomas (IH).
Methodology: A sample size of 60 patients was calculated using WHO calculator. Non probability consecutive sampling was used. Ethical approval and consent forms were taken. Patients were randomly divided into two groups using lottery method. Group A was given oral propranolol and Group B was given topical timolol. Both groups were followed for 3 months for Visual analogue scale of therapeutic response rate. Data was analyzed using SPSS version 24. Chi-square test was applied. P value ≤0.05 was considered significant.
Results:Total 60 infantile hemangioma patients were included in study. Mean age of patients was 5.4months±1.9SD. There were 32(53.3%) male and 28(46.7%) female. Therapeutic response rate was higher in topical timolol as compare to oral propranolol (p=0.003). Adverse effects were significantly higher in oral propranolol group as compare to topical timolol (p=0.000).
Conclusion: Topical timolol is safe and effective treatment in infantile hemangiomas as compare to oral propranolol. Topical timolol poses less risk of inducing adverse effects among infants. Therefore, topical propranolol is recommended for small and superficial infantile hemangiomas.

Key words: Infantile hemangiomas, propranolol, response rate.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Abdul Hameed Khan
Articles by Gulwish Salah u Din
Articles by Jawaria Irshad
Articles by Anam Altaf
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

Khan AH, Din GSu, Irshad J, Altaf A. Oral versus topical propranolol in infantile hemangiomas. RMJ. 2020; 45(3): 611-615.


Web Style

Khan AH, Din GSu, Irshad J, Altaf A. Oral versus topical propranolol in infantile hemangiomas. https://www.rmj.org.pk/?mno=87871 [Access: December 07, 2023].


AMA (American Medical Association) Style

Khan AH, Din GSu, Irshad J, Altaf A. Oral versus topical propranolol in infantile hemangiomas. RMJ. 2020; 45(3): 611-615.



Vancouver/ICMJE Style

Khan AH, Din GSu, Irshad J, Altaf A. Oral versus topical propranolol in infantile hemangiomas. RMJ. (2020), [cited December 07, 2023]; 45(3): 611-615.



Harvard Style

Khan, A. H., Din, . G. S. u., Irshad, . J. & Altaf, . A. (2020) Oral versus topical propranolol in infantile hemangiomas. RMJ, 45 (3), 611-615.



Turabian Style

Khan, Abdul Hameed, Gulwish Salah u Din, Jawaria Irshad, and Anam Altaf. 2020. Oral versus topical propranolol in infantile hemangiomas. Rawal Medical Journal, 45 (3), 611-615.



Chicago Style

Khan, Abdul Hameed, Gulwish Salah u Din, Jawaria Irshad, and Anam Altaf. "Oral versus topical propranolol in infantile hemangiomas." Rawal Medical Journal 45 (2020), 611-615.



MLA (The Modern Language Association) Style

Khan, Abdul Hameed, Gulwish Salah u Din, Jawaria Irshad, and Anam Altaf. "Oral versus topical propranolol in infantile hemangiomas." Rawal Medical Journal 45.3 (2020), 611-615. Print.



APA (American Psychological Association) Style

Khan, A. H., Din, . G. S. u., Irshad, . J. & Altaf, . A. (2020) Oral versus topical propranolol in infantile hemangiomas. Rawal Medical Journal, 45 (3), 611-615.